Journal
AIDS
Volume 26, Issue 13, Pages 1679-1684Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e328356886d
Keywords
first-line antiretroviral therapy; HIV-1 drug resistance; K65R; South Africa; subtype C virus.; tenofovir; virologic failure
Categories
Funding
- Emory University Center for AIDS Research (CFAR) [P30 AI050409]
- Emory School of Medicine Division of Infectious Diseases, NIH [P30 AI60354, K24 RR16482]
- Harvard University Program on AIDS, CDC [U62/CCU123541-01]
- Elizabeth Glaser Pediatric AIDS Foundation as part of Project HEART
- Gilead Foundation
- Abbott
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Gilead
- Merck
- Roche
- ViiV
Ask authors/readers for more resources
Objective: We sought to determine the rate of the K65R mutation in patients receiving tenofovir (TDF)-based antiretroviral therapy (ART) with subtype C HIV infection. Design: Retrospective cohort study. Methods: All patients initiated on stavudine (d4T) with lamivudine (3TC) or TDF with 3TC and a nonnucleoside reverse transcriptase inhibitor at McCord Hospital in Durban, South Africa had their charts reviewed. All patients with virologic failure, defined as a viral load more than 1000 copies/ml after 5 months of a first ART regimen, had genotypic resistance testing performed prospectively using a validated in-house assay. Important resistance mutations were selected based upon published mutations in subtype B virus in the Stanford HIV Drug Resistance database. Results: A total of 585 patients were initiated on TDF-containing first-line ART from 3 August 2010 to 17 March 2011. Thirty-five (6.0%) of these patients had virologic failure and 23 of 33 (69.7%) of the virologic failure patients had the K65R mutation. The median (interquartile range) for the baseline CD4 cell count was 105 cells/mu l (49-209) and viral load at virologic failure was 47 571 copies/ml (20 708-202 000). During the same period, 53 patients were initiated on cl4T-containing regimens. Two (3.8%) of these patients had virologic failure and one of the virologic failure patients had the K65R mutation. Conclusion: Preliminary data show very high rates (>65%) of K65R for patients failing TDF-based first-line regimens at McCord Hospital with few additional nucleoside reverse transcriptase inhibitor mutations compared with subtype B. These rates may reflect faster in-vivo selection, longer time on a failing regimen or transmitted drug resistance. (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available